Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma

NCT07441954 | Not Yet Recruiting Phase 1

• 1 other identifier: IIT2025083
• Study Type: interventional
• Target: 53
• Locations: 0 countries
• Sites: N/A

Brief Summary

To explore the maximum tolerated dose (MTD) of pomalidomide in combination with obinutuzumab in patients with relapsed/refractory indolent lymphomas (including follicular lymphoma, marginal zone lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma) treated with the pomalidomide plus obinutuzumab combination regimen, and to determine the recommended phase II dose (RP2D); concurrently evaluating the efficacy and safety of pomalidomide combined with obinutuzumab in patients with relapsed/refractory indolent lymphomas.

Conditions

Indolent Lymphoma

Outcome Measures

Primary Outcomes (2)

• Recommended Phase II Dose (RP2D)

  The drug dose for Phase 2 clinical trials was determined through dose escalation in Phase 1 clinical trials to identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD).

  day 28 (each cycle is 28 days)

• Phase 2 : Objective response rate，ORR

  defined as the proportion of patients with complete or partial response as assessed by response to induction therapy.

  Up to the end of 6 cycles of treatment(each cycle is 28 days)

Secondary Outcomes (4)

• complete response rate，CRR

  Up to 24 weeks (each cycle is 28 days)

• progression-free survival，PFS

  through study completion, an average of 5 year

• Overall survival，OS

  through study completion, an average of 5 year

• Adverse event rate

  through maintenance therapy completion, an average of 2 years (each cycle is 28 days)

Study Arms (1)

Induction therapy and maintenance therapy of GP

EXPERIMENTAL

1. Phase 1: Dose Escalation Phase. Obinutuzumab administered at 1000 mg on days 1, 8, and 15 (Cycle 1), and day 1 (Cycles 2-6), with a 28-day cycle. Pomalidomide is administered in three dose groups (2 mg, 3 mg, 4 mg) on days 1-21. Dose-limiting toxicity (DLT) is observed during the first cycle to determine the recommended Phase II dose (RP2D). 2. Phase 2: Dose Expansion Phase. Induction Therapy: Obinutuzumab administered at 1000 mg on days 1, 8, and 15 (Cycle 1), and day 1 (Cycles 2-6), with pomalidomide at RP2D on days 1-21, in 28-day cycles for 6 cycles. Maintenance Therapy ：Pomalidomide: For complete response (CR) patients, half of the RP2D dose; for PR patients, full RP2D dose, on days 1-21 (Cycles 7-18). Obinutuzumab: 1000 mg administered on day 1 of every 2 cycles

Drug: Induction therapy of GP(Pomalidomide+Obinutuzumab）; Drug: maintenance therapy of GP(Pomalidomide+Obinutuzumab）

Interventions

Induction therapy of GP(Pomalidomide+Obinutuzumab） DRUG

Phase 1: Dose Escalation Phase. Obinutuzumab administered at 1000 mg on days 1, 8, and 15 (Cycle 1), and day 1 (Cycles 2-6), with a 28-day cycle. Pomalidomide is administered in three dose groups (2 mg, 3 mg, 4 mg) on days 1-21. Dose-limiting toxicity (DLT) is observed during the first cycle to determine the recommended Phase II dose (RP2D). 2、Phase 2: Dose Expansion Phase. Induction Therapy: Obinutuzumab administered at 1000 mg on days 1, 8, and 15 (Cycle 1), and day 1 (Cycles 2-6), with pomalidomide at RP2D on days 1-21, in 28-day cycles for 6 cycles.

Induction therapy and maintenance therapy of GP

maintenance therapy of GP(Pomalidomide+Obinutuzumab） DRUG

Maintenance Therapy ：Pomalidomide: For complete response (CR) patients, half of the RP2D dose; for PR patients, full RP2D dose, on days 1-21 (Cycles 7-18). Obinutuzumab: 1000 mg administered on day 1 of every 2 cycles

Induction therapy and maintenance therapy of GP

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years old, regardless of gender;
• Histopathologically confirmed CD20+ indolent lymphoma (FL, MZL, or SLL), WHO grade 1-3a;.
• Relapsed or refractory disease after at least one prior line of therapy;.
• ECOG-PS 0-2;
• At least one measurable lesion;
• Bone marrow hematopoietic function is basically normal. Complete blood count: white blood cell count \>3000/uL, absolute neutrophil count ≥1.5×10\^9/L (use of granulocyte colony-stimulating factor is permitted), platelet count ≥75×10\^9/L (transfusion is allowed to achieve this minimum platelet count), hemoglobin ≥9.0g/dL (prior red blood cell transfusion or use of recombinant human erythropoietin is permitted). If abnormal peripheral blood indices are caused by lymphoma infiltration of bone marrow or spleen, the investigator may exercise discretion in determining eligibility for enrollment.
• Normal function of major organs: Liver function: serum bilirubin ≤2.0×ULN, serum ALT and AST ≤2.5×ULN; Renal function: creatinine clearance \>30mL/min;.
• The investigator judged that the expected survival period was ≥3 months;
• The patient was fully informed and signed the informed consent form;.
• Female subjects must use effective contraception, not be pregnant, and agree to practice contraception during the trial and after the study ends. Male subjects must agree to practice contraception during the trial and for 30 days after the last treatment.

You may not qualify if:

• Any other type of lymphoma, including Burkitt lymphoma;
• The investigator confirms that the patient may progress to aggressive lymphoma.
• Patients with contraindications or allergies to the investigational drug.
• History of VTE or cerebral infarction prior to treatment;.
• Patients who have undergone major surgery within 30 days prior to enrollment that may significantly impair physical condition or increase the risk of thrombosis, or who have scheduled surgery during the study period. Subjects planning to undergo minor surgical procedures under local anesthesia that do not significantly affect physical condition or markedly increase thrombosis risk may participate in the study.
• Patients with uncontrolled or severe cardiovascular diseases, including myocardial infarction within 3 months prior to enrollment, unstable coronary artery disease, uncontrolled chronic congestive heart failure, Class III-IV heart failure as defined by the New York Heart Association (NYHA), or clinically significant pericardial disease;.
• Uncontrolled hypertension.
• Uncontrolled diabetes.
• Uncontrolled active infection, or acute active infection, requiring systemic use of antibiotics, antiviral or antifungal medications within two weeks prior to the first dose.
• HIV-positive.
• Active hepatitis B or C.
• History of other malignancies within 3 years prior to the first study drug administration.
• Any clinically significant medical condition or disorder that the investigator considers may affect compliance with the experimental protocol or the subject's ability to provide informed consent.
• The subject is a pregnant or lactating female.
• Patients with severe physical or mental illnesses that may interfere with participation in this clinical study as determined by the protocol or investigator's judgment; or conditions such as drug abuse, medical, psychological, or social circumstances that may affect the subject's participation or evaluation of study results.

Sponsors & Collaborators

• Institute of Hematology & Blood Diseases Hospital, China: lead

Central Study Contacts

Shuhua Yi, Dr

CONTACT

+86-022-23909106; yishuhua@ihcams.ac.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2026
• First Posted: March 2, 2026
• Study Start: March 20, 2026
• Primary Completion (Estimated): December 5, 2027
• Study Completion (Estimated): December 31, 2029
• Last Updated: March 2, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share